Evidence map›Paper›PMID 29215279›Full record

ArticleJournal of medicinal chemistry2018

Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.

Raghupathi Neelarapu, Jordany R Maignan, Cynthia L Lichorowic, Andrii Monastyrskyi, Tina S Mutka, Alexis N LaCrue, Lynn D Blake, Debora Casandra, Sherwin Mashkouri, Jeremy N Burrows and 3 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 38 citations in OpenAlex.

  1. Legacy 4(1ACS infectious diseases · 2026
    Article
  2. Article
  3. Optimization of diastereomeric dihydropyridines as antimalarials.European journal of medicinal chemistry · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. 7-ACS infectious diseases · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Raghupathi NeelarapuDepartment of Chemistry, University of South Florida , CHE 205, 4202 East Fowler Avenue, Tampa, Florida 33620, United States.
Jordany R MaignanDepartment of Chemistry, University of South Florida , CHE 205, 4202 East Fowler Avenue, Tampa, Florida 33620, United States.
Cynthia L LichorowicDepartment of Chemistry and Chemical Biology, Northeastern University , 102 Hurtig Hall, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
Andrii MonastyrskyiDepartment of Chemistry, University of South Florida , CHE 205, 4202 East Fowler Avenue, Tampa, Florida 33620, United States.
Tina S MutkaDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Alexis N LaCrueDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Lynn D BlakeDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Debora CasandraDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Sherwin MashkouriDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Jeremy N BurrowsMedicines for Malaria Venture , 20, Route de Pré-Bois, P.O. Box 1826, 1215 Geneva, Switzerland.
Paul A WillisMedicines for Malaria Venture , 20, Route de Pré-Bois, P.O. Box 1826, 1215 Geneva, Switzerland.
Dennis E KyleDepartment of Global Health, College of Public Health, University of South Florida , 3720 Spectrum Boulevard, Suite 304, Tampa, Florida 33612, United States.
Roman ManetschDepartment of Chemistry and Chemical Biology, Northeastern University , 102 Hurtig Hall, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.ORCID 0000-0001-7038-6867
University of South Florida · USMedicines for Malaria Venture · CHNortheastern University · US

Funding

Drugs targeting erythrocytic and exoerythrocytic stages of malariaR01GM097118 · NIGMS · UNIVERSITY OF SOUTH FLORIDA · PI MANETSCH, ROMAN · 2011 to 2015
$1.3M
NIGMS NIH HHS R01 GM097118
6 · The paper itself

Abstract

Malaria deaths have been decreasing over the last 10-15 years, with global mortality rates having fallen by 47% since 2000. While the World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) to combat malaria, the emergence of artemisinin resistant strains underscores the need to develop new antimalarial drugs. Recent in vivo efficacy improvements of the historical antimalarial ICI 56,780 have been reported, however, with the poor solubility and rapid development of resistance, this compound requires further optimization. A series of piperazine-containing 4(1H)-quinolones with greatly enhanced solubility were developed utilizing structure-activity relationship (SAR) and structure-property relationship (SPR) studies. Furthermore, promising compounds were chosen for an in vivo scouting assay to narrow selection for testing in an in vivo Thompson test. Finally, two piperazine-containing 4(1H)-quinolones were curative in the conventional Thompson test and also displayed in vivo activity against the liver stages of the parasite.

Indexed as

AnimalsAntimalarialsDrug DesignHumansMicePiperazinePlasmodium falciparumQuinolonesSolubilityStructure-Activity RelationshipAntimalarialsPiperazineQuinolones

Identifiers

PMID29215279
PMCPMC6610884
OpenAlexW2775784848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.